Mr. Alex Blodgett reports

CHINOOK JOINS FORCES WITH A LEADING GERMAN PHARMACEUTICAL CONSULTING COMPANY

Chinook Tyee Industry Ltd. has entered into a consulting agreement with a leading German pharmaceutical and medical consulting company, pursuant to which, among other things, the consultant shall evaluate and confirm that medical cannabis produced by a Canadian licensed producer (LP) of cannabis that has entered into a supply agreement with Chinook meets European Union good manufacturing practice (EU-GMP) regulations for importing medical cannabis into Germany from Canada.

Chinook's business is to import pharmaceutical-grade (EU-GMP) medical cannabis produced by LPs into Germany. EU-GMP certification is an internationally recognized system that ensures that pharmaceutical goods, including medical cannabis, meet the highest consumer health and safety standards. Canadian cannabis production and operating standards need to be upgraded to EU-GMP standards and receive EU-GMP certification from a German state before a LP is able to import medical cannabis into Germany. Upon entering a supply arrangement with a LP, Chinook conducts a gap analysis with its German business partners to determine any required EU-GMP upgrades. Upon passing an audit of any upgrades, Chinook arranges for EU-GMP certification by applicable state authorities in Germany. After an LP has obtained EU-GMP certification from a German state, Chinook and such LP then arrange for the necessary permits to import medical cannabis to Germany from Canada.

"Germany, whose medical cannabis industry is estimated to be valued at 7.7 billion euros by 2028, is experiencing a supply shortage and is dependent on imports predominantly from Canada, which is the largest and most experienced producers of cannabis in the world," according to Alex Blodgett, chief executive officer of Chinook. "Chinook's business is to supply the German medical market with the highest-quality medical cannabis from Canada."

"Germany is the largest medical cannabis market in the globally and will set the pharmaceutical and health care insurance coverage standards for Europe as the region begins to legalize medical cannabis," commented Dr. Stefan Feuerstein, managing director of Chinook's German subsidiary, AMP Alternative Medical Products GmbH.

About Chinook Tyee Industry Ltd.

Chinook is a German-managed investment company with two European subsidiaries, AMP Alternative Medical and Mercury Partners & Company PLC. AMP Alternative's business is to import pharmaceutical-grade (EU-GMP) cannabis produced by Canadian licensed producers into Germany. AMP Alterative, in co-operation with its business partners, will provide EU-GMP audit, logistical, transportation, importation and other related services for the importation of medical cannabis into Germany. Mercury Partners & Company is a Malta-based investment company.

We seek Safe Harbor.